 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
| Dimebon™ |
|
|
|
|
|
|
|
|
|
 |
First Pivotal Trial Successfully Completed |
|
5/5 Endpoints Met |
|
Confirmatory Phase 3 Clinical Trial to Begin Q208 |
|
| Alzheimer’s Disease |
 |
|
|
 |
 |
| Huntington’s Disease |
|
|
|
|
|
|
|
|
|
|
Phase 2 Underway |
|
Data Expected Q208 |
|
|
| MDV3100 |
|
|
|
|
|
|
|
|
|
|
Phase 1-2 Clinical Trial Underway |
|
Initial Data Positive |
|
Final Data Expected 2008 |
|
|
 |
|
 |
|
|
|
Medivation’s business is built on the identification and rapid development of product candidates that show breakthrough potential in important human diseases with suboptimal or ineffective current therapies. Our current portfolio consists of small molecule drugs in clinical development to treat three large, unmet medical needs—Alzheimer’s disease, Huntington’s disease and hormone-refractory prostate cancer.
Dimebon™, our lead product candidate, is an orally-available, small-molecule agent that is in clinical testing for the treatment of Alzheimer’s and Huntington’s diseases—progressive, devastating conditions with limited treatment options. Based on the clinical and preclinical data generated to date, Medivation believes that Dimebon operates by a novel mechanism of action and may exert a neuroprotective effect in multiple areas of the central nervous system.
MDV3100, our lead candidate for hormone-refractory prostate cancer, is a small molecule compound that has been shown in preclinical studies to block both hormone-refractory and hormone-sensitive prostate cancer better than currently available therapies. Men with prostate cancer that no longer responds to hormonal therapy (hormone-refractory prostate cancer) have few treatment options and a poor prognosis.
|
